Clinical trial · Interventional
The Validation of a Novel Adherence Method for Oral Oncolytics
NCT03561272CI-TRIAL-00041009completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| POD | Other | — | UNRESOLVED |
| Smart Phone Application | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- Standard Patient Reported Adherence
- description
- Adherence assessment via phone call or in person
- type
- ACTIVE_COMPARATOR
- label
- Smart Phone Application
- description
- Adherence assessment via phone app
- interventionNames
- Other: Smart Phone Application
- type
- EXPERIMENTAL
- label
- POD and Smart Phone Application
- description
- Adherence assessment via phone app partnered with an automated dispensing machine, a "Pod."
- interventionNames
- Other: Smart Phone Application
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must be \> 18 years of age * Must have a smart phone * Must be able to have their oral oncolytic filled at the University of Michigan Comprehensive Cancer Center pharmacy and be newly prescribed Capecitabine (Xeloda). Exclusion Criteria: * Patients who do not have a smart phone * Patients who have a serious mental illness or cognitive impairment, e.g., psychosis or dementia. * Patients who do not speak English * Patients who cannot fill their oral oncolytic prescription at the University of Michigan Comprehensive Cancer Center Pharmacy
References
Publications (0)
Data not yet available
No reference posted for this study.